Global intelligence platform

Global antimicrobial resistance intelligence platform powered by WHO, ECDC, and public surveillance data.

Currently in early development. Combining surveillance data from the world's leading health organizations into forecasts and decision support — built by a microbiologist, for microbiologists.

Join early access → See data sources
app.amrlytics.ai / surveillance
Live
AMRlytics Surveillance Dashboard — real-time AMR resistance trends for Acinetobacter spp. across Argentina, Bosnia and Herzegovina, and Brazil (2018–2023)
Surveillance Dashboard · Acinetobacter spp. / Amikacin ECDC EARS-Net + WHO GLASS · 66 countries
3,369
Surveillance rows
Loaded from WHO + ECDC
25
Years of history
2000–2024 ECDC coverage
66+
Countries covered
WHO GLASS + ECDC EARS-Net
5yr
Forecast horizon
Prophet · experimental

01 — Data networks

Three surveillance networks.
One unified platform.

AMRlytics integrates data from the world's most authoritative AMR surveillance systems, normalizes it into a unified schema, and makes it queryable in seconds.

WHO
WHO GLASS
Global Antimicrobial Resistance and Use Surveillance System. 90+ countries, bloodstream, urinary, and gastrointestinal infections.
GLOBAL · 2018–2023
ECDC
ECDC EARS-Net
European Antimicrobial Resistance Surveillance Network. 30 EU/EEA countries, 25 years of history per pathogen.
EUROPE · 2000–2024
CDC
CDC AR&PSP
National Antimicrobial Resistance Monitoring System. US-specific state-level data, healthcare-associated infections.
UNITED STATES · COMING SOON
REG
Regional sources
GCC health councils, South Asian surveillance programs, and curated national reports from underrepresented regions.
SOUTH ASIA · GCC · IN PROGRESS

02 — Platform capabilities

Built for researchers,
hospitals, pharma & public health.

01 — Surveillance

Global AMR Surveillance

WHO and ECDC datasets unified into one queryable experience. Filter by pathogen, antibiotic, country, infection type, and year. 3,369+ data rows and growing.

● Beta · WHO + ECDC integrated
02 — Forecasting

AI Resistance Forecasting

Prophet time-series models trained on up to 25 years of surveillance data. Project resistance trends with confidence intervals. Honest uncertainty quantification, clearly labeled experimental.

● Beta · Prophet model
03 — Intelligence

AMR Copilot

Ask clinical and epidemiological questions in plain language. Get answers grounded in real surveillance data. Built on RAG architecture to prevent hallucination.

In development · Pilot access
04 — Reports

Intelligence Reports

Auto-generated, citable intelligence reports per country, pathogen, and antibiotic class. Downloadable as PDF, shareable as permanent URLs. Designed for policy and research use.

Planned · Q4 roadmap

Early validation

Built with input from researchers
working on AMR daily.

AMRlytics is being validated with microbiologists, public health researchers, and clinicians across multiple institutions. Testimonials and pilot partner endorsements will appear here as we collect them.

"

Researcher feedback will appear here once early-access partners begin using the platform.

Pilot partner
Coming soon
"

Institutional pilot quotes from public health departments and research labs will be added here.

Institutional partner
Coming soon
"

Clinical validation feedback from infectious disease specialists and microbiologists will appear here.

Clinical partner
Coming soon

Want to be a pilot partner? Get in touch →

03 — Methodology

Transparent.
Scientifically
defensible.

AMRlytics standardizes multi-source surveillance data, harmonizes pathogen nomenclature, maps antibiotic classes across naming conventions, and applies transparent forecasting models with documented limitations.

⚠ Important disclaimer AMRlytics is a surveillance and forecasting intelligence tool. It is not a clinical decision support system and does not provide medical advice. Forecasts are based on historical trends and do not account for future policy changes, new antibiotic approvals, or epidemiological events. Always consult a qualified clinician or microbiologist before making treatment decisions.

04 — Pilot program

Who we're looking for.

AMRlytics is in active validation. We're inviting a small group of professionals to access the full platform free of charge — in exchange for honest feedback that shapes the product.

Profile 1
Microbiologists & researchers
Working on AMR surveillance, resistance mechanisms, One Health, or epidemiology.
  • Test resistance trend queries for your pathogens of interest
  • Evaluate forecasting methodology and confidence intervals
  • Provide feedback on scientific accuracy and limitations
  • Potential co-authorship on the AMRlytics methods preprint
Apply for pilot access→
Profile 2
Public health & clinical professionals
Clinicians, pharmacists, infection control leads, and health department staff working with resistance data.
  • Evaluate whether surveillance alerts match clinical reality
  • Test the actionable insights and alternative antibiotic data
  • Identify which features would actually save time in practice
  • Help define what "useful" looks like for stewardship teams
Apply for pilot access→
Profile 3
Pharma R&D & health institutions
Drug development teams, ministries of health, hospital networks, and NGOs working on AMR programs.
  • Evaluate data coverage for target regions and pathogens
  • Test benchmarking for therapeutic opportunity identification
  • Discuss integration with existing surveillance infrastructure
  • Shape the roadmap for enterprise and API features
Get in touch→

Pilot access is free · No commitment required · Feedback shapes the platform

Help shape the future
of AMR intelligence.

AMRlytics is in early development. We're inviting microbiologists, public health researchers, and clinicians to join early access, test the platform, and tell us what's actually useful.